Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Mar 29, 2025
Product Development
Bispecifics for I&I: Bypassing combination complexity
At least 30 companies have bispecific antibodies in development for autoimmune and inflammatory diseases
BioCentury | Mar 18, 2025
Management Tracks
Zenas names Lisa von Moltke head of R&D and CMO
Plus: CBC’s Lan Kang becomes CEO of Azkarra, and updates from Ionctura, Sunbird and Surf Bio
BioCentury | Mar 12, 2025
Product Development
Autoimmune CAR T companies compete for resources
Crowding in the autoimmune CAR T field brings recruitment challenges
BioCentury | Feb 28, 2025
Product Development
Caribou: Solving the allogeneic problem with CRISPR
Caribou selected a de-risked target and modality to take on multiplexed editing
BioCentury | Feb 25, 2025
Product Development
Indication selection: Lessons learned from the CRISPR-Cas9 story
Founding CEOs of gene editing companies discuss their pipeline strategies and lessons learned
BioCentury | Feb 25, 2025
Management Tracks
After leaving FDA, Cavazzoni joins Pfizer as CMO
Plus: CFO hires at Nuclera, Crinetics, Terns and updates from Xeris, Inhibikase and Climb Bio
BioCentury | Feb 1, 2025
Data Byte
Safety of Alzheimer’s therapy again under scrutiny at EMA’s CHMP
Plus: Pfizer’s Tivdak gets CHMP nod, as Daiichi’s Dato-Dxd receives positive opinion in one indication, gets withdrawn in another
BioCentury | Jan 31, 2025
Editor's Commentary
Crippling NIH is handing China a huge advantage: a Perspective
The price of chipping away at the nation’s crown jewel
Items per page:
1 - 10 of 1091